Biolegend, 405201, FITC Streptavidin, 100μg

Streptavidin binds to biotin with high affinity. Streptavidin-fluorescein isothiocyanate (FITC) is useful for detecting biotinylated antibodies. The excitation of FITC by 488 nm laser light induces a light emission maximum of 520 nm.
100μg
Verified Reactivity: Human, Mouse, Rat, All Species
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: Streptavidin is conjugated with FITC under optimal conditions.
Concentration: 0.5 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling: The Streptavidin-FITC solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested ICFC - Verified
Recommended Usage: Each lot of this Streptavidin-FITC is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the FITC conjugation. For immunofluorescent staining, the recommended use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl staining volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)
Application Notes: Streptavidin-FITC is useful as a second step reagent for indirect immunofluorescent staining, in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-FITC is 60 kD and Streptavidin alone is 52 kD.
Application References(PubMed link indicates BioLegend citation): Schmutz S, et al. 2009. J. Immunol. 183:2217. PubMed Cho HY, et al. 2009. Immunol Lett. 127:39. PubMed de Wispelaere D, et al. 2012. J. Virol. 86:7072. PubMed Fukuoka A, et al. 2013. Int Immunol. PubMed Giltiay NV, et al. 2013. J Exp Med. 25:373. PubMed Lee JH, et al. 2014. J Rheumatol. 41:2425. PubMed
Product Citations: Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed Pymm P, et al. 2022. iScience. 25:105259. PubMed Yu H, et al. 2023. Nat Commun. 14:1058. PubMed Luo Y, et al. 2023. Cell Discov. 9:40. PubMed Chen K, et al. 2023. Gut Pathog. 15:28. PubMed Kemble S, et al. 2022. Blood Adv. 6:2932. PubMed Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed Lorenzo-Martín LF, et al. 2022. Oncogene. 41:3341. PubMed Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed Parnigoni A, et al. 2022. Matrix Biol. 109:140. PubMed Georgiadis C, et al. 2021. Leukemia. . PubMed Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed Krishack PA, et al. 2019. JCI Insight. 4:6. PubMed Sasaki N, Itakura Y, Toyoda M 2017. Stem Cell Res Ther. 10.1186/s13287-017-0534-1. PubMed Suarez-Calvet X, et al. 2021. FASEB J. 35:e21819. PubMed Zaitouna AJ, et al. 2020. Bio Protoc. 10:e3655. PubMed Yang M 2012. J Virol. 86:7072. PubMed Pan H, et al. 2020. Mol Psychiatry. . PubMed Wang Y, et al. 2021. Nat Commun. 12:2343. PubMed Sánchez-Salguero E, et al. 2021. Front Immunol. 12:712130. PubMed Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed Li S, et al. 2016. PLoS One. 11: 0163893. PubMed Lee J, et al. 2014. J Rheumatol. 41:2425. PubMed Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed Noviski M, et al. 2018. Elife. 7:e35074. PubMed Zhang Y, et al. 2019. JCI Insight. 4:2. PubMed Yan R, et al. 2021. Cell Death Dis. 12:955. PubMed Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed Schmutz S, et al. 2009. J Immunol. 183:2217. PubMed Delacher M, et al. 2020. Immunity. 52:295. PubMed Cheng LS, et al. 2022. J Transl Med. 20:415. PubMed Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed Bülow JM, et al. 2022. Front Endocrinol (Lausanne). 13:1016057. PubMed Oda Y, et al. 2021. Sci Adv. 7:eabj6895. PubMed Li X, et al. 2021. Oncol Lett. 22:788. PubMed Cho H, et al. 2009. Immunol Lett. 127:39. PubMed Buffolo M, et al. 2019. Cell Rep. 29:270. PubMed Wang Y, et al. 2022. Front Immunol. 13:847581. PubMed Hensel JA, et al. 2019. Mol Ther Oncolytics. 12:41. PubMed Lin Y, et al. 2012. PLoS One. 7:e30507. PubMed Fukuoka A, et al. 2013. Int Immunol. 25:373. PubMed Giltiay N, et al. 2013. J Exp Med. 210:2773. PubMed Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed SL C, et al. 2016. JCI Insight. 1: 83116. PubMed Mödinger Y, et al. 2018. J Cell Mol Med. 22:6002. PubMed Hamester F, et al. 2022. Cells. 11:. PubMed Laurin M, et al. 2019. Elife. 8. PubMed Sturmlechner I, et al. 2021. Science. 374:eabb3420. PubMed Geng S, et al. 2016. Nat Commun. 7:13436. PubMed Zhu Z, et al. 2017. Int J Biochem Cell Biol. 10.1016/j.biocel.2017.04.003. PubMed Lindsay RS, et al. 2021. J Exp Med. 218:. PubMed Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
Gene ID: NA
UniProt: View information about Biotin on UniProt.org
Regulatory Status: RUO
Other Names: Streptavidin-Fluorescein Isothiocyanate, SAv-FITC